Magnetic Resonance Spectroscopy: An in Vivo Molecular Imaging Biomarker for Parkinson's Disease?

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Ciurleo, Rosella ^a   Di Lorenzo, Giuseppe ^a   Bramanti, Placido ^a   Marino, Silvia ^a,b  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; APOMORPHINE; CARBIDOPA PLUS LEVODOPA; CHOLINE; CREATINE; CREATINE PHOSPHATE; GLUTATHIONE; INOSITOL; LACTIC ACID; LEVODOPA; N ACETYLASPARTIC ACID; PERGOLIDE; ASPARTIC ACID; BIOLOGICAL MARKER; N-ACETYLASPARTATE;

BRAIN DEPTH STIMULATION; DOPAMINERGIC NERVE CELL; EARLY DIAGNOSIS; HUMAN; IN VIVO STUDY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PARKINSONISM; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; ANALOGS AND DERIVATIVES; BRAIN; METABOLISM; MOLECULAR IMAGING; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ASPARTIC ACID; BIOLOGICAL MARKERS; BRAIN; CHOLINE; CREATINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR IMAGING; PARKINSON DISEASE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84930913224     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/519816     Document Type: Review

References (48)

1. J. Jankovic, "Parkinsons disease: clinical features and diagnosis, " Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 4, pp. 368-376, 2008.
2. J. A. Obeso, M. C. Rodriguez-Oroz, M. Rodriguez, et al., "Pathophysiology of the basal ganglia in Parkinsons disease, " Trends in Neurosciences, vol. 23, supplement 1, no. 10, pp. S8-S19, 2000.
3. T. Yasuda, Y. Nakata, and H. Mochizuki, "α-Synuclein and neuronal cell death, " Molecular neurobiology, vol. 47, no. 2, pp. 466-483, 2013.
4. P. Riederer and S. Wuketich, "Time course of nigrostriatal degeneration in Parkinson's disease: a detailed study of influential factors in human brain amine analysis, " Journal of Neural Transmission, vol. 38, no. 3-4, pp. 277-301, 1976.
5. H. Braak, U. Rub, D. Sandmann-Keil, et al., "Parkinsons disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system, " Acta Neuropathologica, vol. 99, no. 5, pp. 489-495, 2000.
6. A. Lin, B. D. Ross, K. Harris, and W. Wong, "Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making, " NeuroRx, vol. 2, no. 2, pp. 197-214, 2005.
7. Y. Rosen and R. E. Lenkinski, "Recent advanced in magnetic resonance neurospectroscopy, " Neurotherapeutics, vol. 4, no. 3, pp. 330-345, 2007.
8. B. Ross and S. Bluml, "Magnetic resonance spectroscopy of the human brain, "TheAnatomical Record, vol. 265, no. 2, pp. 54-84, 2001.
9. C. E. Clarke and M. Lowry, "Basal ganglia metabolite concentrations in idiopathic Parkinsons disease and multiple system atrophymeasured by protonmagnetic resonance spectroscopy, " European Journal of Neurology, vol. 7, no. 6, pp. 661-665, 2000.
10. B.-Y. Choe, J.-W. Park, K.-S. Lee, et al., "Neuronal laterality in Parkinsons disease with unilateral symptom by in vivo 1H magnetic resonance spectroscopy, " Investigative Radiology, vol. 33, no. 8, pp. 450-455, 1998.
11. J. ONeill, N. Schuff, W. J. Marks Jr., R. Feiwell, M. J. Aminof f, and M. W. Weiner, "Quantitative 1Hmagnetic resonance spectroscopy and MRI of Parkinsons disease, " Movement Disorders, vol. 17, no. 5, pp. 917-927, 2002.
12. S. D. Taylor-Robinson, N. Turjanski, S. Bhattacharya, et al., "A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinsons disease, " Metabolic Brain Disease, vol. 14, no. 1, pp. 45-55, 1999.
13. M. T. M. Hu, S. D. Taylor-Robinson, K. Ray Chaudhuri, et al., "Evidence for cortical dysfunction in clinically non-demented patients with Parkinsons disease: a proton MR spectroscopy study, " Journal of Neurology, Neurosurgery & Psychiatry, vol. 67, no. 1, pp. 20-26, 1999.
14. C. Lucetti, P. Del Dotto, G. Gambaccini, et al., "Protonmagnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinsons disease patients, " Neurological Sciences, vol. 22, no. 1, pp. 69-70, 2001.
15. R. M. Camicioli, J. R. Korzan, S. L. Foster, et al., "Posterior cingulate metabolic changes occur in Parkinsons disease patients without dementia, " Neuroscience Letters, vol. 354, no. 3, pp. 177-180, 2004.
16. R. M. Camicioli, C. C. Hanstock, T. P. Bouchard, M. Gee, N. J. Fisher, and W. R. W. Martin, "Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinsons disease, " Movement Disorders, vol. 22, no. 3, pp. 382-386, 2007.
17. C. A. Davie, G. K. Wenning, G. J. Barker, et al., "Differentiation of multiple system atrophy from idiopathic Parkinsons disease using proton magnetic resonance spectroscopy, " Annals of Neurology, vol. 37, no. 2, pp. 204-210, 1995.
18. C. J. Cruz, M. J. Aminof f, D. J. Meyerhof f, S. H. Graham, and M. W. Weiner, "Proton MR spectroscopic imaging of the striatum in parkinson's disease, "Magnetic Resonance Imaging, vol. 15, no. 6, pp. 619-624, 1997.
19. G. Tedeschi, I. Litvan, S. Bonavita, et al., "Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinsons disease and corticobasal degeneration, " Brain, vol. 120, no. 9, pp. 1541-1552, 1997.
20. C. E. Clarke, M. Lowry, and A. Horsman, "Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinsons disease measured by proton magnetic resonance spectroscopy, " Movement Disorders, vol. 12, no. 3, pp. 297-301, 1997.
21. A. Groger, G. Chadzynski, J. Godau, D. Berg, and U. Klose, "Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinsons disease, " European Radiology, vol. 21, no. 9, pp. 1962-1969, 2011.
22. B. E. Levin, H. L. Katzen, A. Maudsley, et al., "Whole-brain proton MR spectroscopic imaging in Parkinsons disease, " Journal of Neuroimaging, vol. 24, no. 1, pp. 39-44, 2014.
23. H. R. Griffith, O. C. Okonkwo, T. O'Brien, and J. A. den Hollander, "Reduced brain glutamate in patients with Parkinson's disease, " NMR in Biomedicine, vol. 21, no. 4, pp. 381-387, 2008.
24. G. Oz, M. Terpstra, I. Tkac, et al., "Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABAconcentrations, "Magnetic Resonance inMedicine, vol. 55, no. 2, pp. 296-301, 2006.
25. U. E. Emir, P. J. Tuite, and G. Oz, "Elevated pontine and putamenal gaba levels in mild-moderate parkinson disease detected by 7 tesla protonMRS, " PLoS ONE, vol. 7, no. 1, Article ID e30918, 2012.
26. A. Di Costanzo, F. Trojsi, M. Tosetti, et al., "Proton MR spectroscopy of the brain at 3 T: an update, " European Radiology, vol. 17, no. 7, pp. 1651-1662, 2007.
27. N. Kickler, P. Krack, V. Fraix, et al., "Glutamate measurement in Parkinsons disease using MRS at 3 T field strength, " NMR in Biomedicine, vol. 20, no. 8, pp. 757-762, 2007.
28. X. T. Fan, F. Zhao, Y. Ai, et al., "Cortical glutamate levels decrease in a non-human primate model of dopamine deficiency, " Brain Research, vol. 1552, pp. 34-40, 2014.
29. C. Chassain, G. Bielicki, C. Keller, J.-P. Renou, and F. Durif, "Metabolic changes detected in vivo by 1H MRS in the MPTPintoxicatedmouse, " NMRin Biomedicine, vol. 23, no. 6, pp. 547-553, 2010.
30. H.-C. Gao, H. Zhu, C.-Y. Song, et al., "Metabolic changes detected by ex vivo high resolution 1H NMR spectroscopy in the striatum of 6-OHDA-induced Parkinsons rat, " Molecular Neurobiology, vol. 47, no. 1, pp. 123-130, 2013.
31. P. Bagga, A. N. Chugani, K. S. Varadarajan, and A. B. Patel, "In vivo NMR studies of regional cerebral energetics in MPTP model of Parkinson's disease: recovery of cerebral metabolism with acute levodopa treatment, " Journal of Neurochemistry, vol. 127, no. 3, pp. 365-377, 2013.
32. A. H. V. Schapira, M. Gu, J.-W. Taanman, et al., "Mitochondria in the etiology and pathogenesis of Parkinsons disease, " Annals of Neurology, vol. 44, no. 3, pp. S89-S98, 1998.
33. B. C. Bowen, R. E. Block, J. Sanchez-Ramos, et al., "Proton MR spectroscopy of the brain in 14 patients with Parkinson disease, " The American Journal of Neuroradiology, vol. 16, no. 1, pp. 61-68, 1995.
34. S. J. G. Lewis, J. M. Shine, S. Duffy, G. Halliday, and S. L. Naismith, "Anterior cingulate integrity: executive and neuropsychiatric features in Parkinsons disease, " Movement Disorders, vol. 27, no. 10, pp. 1262-1267, 2012.
35. K. Nie, Y. Zhang, B. Huang, et al., "Marked N-acetylaspartate and choline metabolite changes in Parkinsons disease patients with mild cognitive impairment, " Parkinsonism and Related Disorders, vol. 19, no. 3, pp. 329-334, 2013.
36. A. Brand, C. Richter-Land sberg, and D. Leibfritz, "Multinuclear NMR studies on the energy metabolism of glial and neuronal cells, "Developmental Neuroscience, vol. 15, no. 3-5, pp. 289-298, 1993.
37. K. Abe, H. Terakawa, M. Takanashi, et al., "Proton magnetic resonance spectroscopy of patients with parkinsonism, " Brain Research Bulletin, vol. 52, no. 6, pp. 589-595, 2000.
38. C. A. Guevara, C. R. Blain, D. Stahl, D. J. Lythgoe, P. N. Leigh, and G. J. Barker, "Quantitative magnetic resonance spectroscopic imaging in Parkinsons disease, progressive supranuclear palsy and multiple systematrophy, " European Journal of Neurology, vol. 17, no. 9, pp. 1193-1202, 2010.
39. F. Federico, I. L. Simone, V. Lucivero, et al., "Usefulness of proton magnetic resonance spectroscopy in differentiating parkinsonian syndromes, " Italian Journal of Neurological Sciences, vol. 20, no. 4, pp. 223-229, 1999.
40. H. Watanabe, H. Fukatsu, M. Katsuno, et al., "Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker, " Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 1, pp. 103-109, 2004.
41. A. Groger, B. Bender, I. Wurster, G. L. Chadzynski, U. Klose, and D. Berg, "Differentiation between idiopathic and atypical parkinsonian syndromes using three-dimensional magnetic resonance spectroscopic imaging, " Journal of Neurology, Neurosurgery & Psychiatry, vol. 84, no. 6, pp. 644-649, 2013.
42. M. J. Firbank, R. M. Harrison, and J. T. OBrien, "A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinsons disease, " Dementia and Geriatric Cognitive Disorders, vol. 14, no. 2, pp. 64-76, 2002.
43. E. Hattingen, J. Magerkurth, U. Pilatus, et al., "Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinsons disease, " Brain, vol. 132, no. 12, pp. 3285-3297, 2009.
44. N. Weiduschat, X. Mao, M. F. Beal, M. J. Nirenberg, D. C. Shungu, and C. Henchcliffe, "Usefulness of proton and phosphorus MR spectroscopic imaging for early diagnosis of Parkinson's disease, " Journal of Neuroimaging, 2013.
45. B. A. Holshouser, M. Komu, H. E. Moller, et al., "Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinsons disease: a multicenter pilot study, " Magnetic Resonance in Medicine, vol. 33, no. 5, pp. 589-594, 1995.
46. C. M. Ellis, G. Lemmens, S. C. R. Williams, et al., "Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinsons disease: a proton magnetic resonance spectroscopy study, " Neurology, vol. 49, no. 2, pp. 438-444, 1997.
47. C. Lucetti, P. Del Dotto, G. Gambaccini, et al., "Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study, " Movement Disorders, vol. 22, no. 15, pp. 2170-2175, 2007.
48. C. Llumiguano, N. Kovacs, Z. Usprung, A. Schwarcz, T. P. Doczi, and I. Balas, "1H-MRS experiences after bilateral DBS of the STN in Parkinsons disease, " Parkinsonism & Related Disorders, vol. 14, no. 3, pp. 229-232, 2008.